The perspectives of the application of phage therapy in chronic bacterial prostatitis.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  FEMS Immunology & Medical Microbiology

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1574-695X.2010.00723.xPMID 20698884
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bacteriophage resistance mechanisms

  2010cited by this paper
• Phage therapy in clinical practice: treatment of human infections.

  2010cited by this paper
• Bacteriophages and cancer

  2010cited by this paper
• Clinical significance of IL-2, IL-10, and TNF-alpha in prostatic secretion of patients with chronic prostatitis.

  2010cited by this paper
• 374 PATHOGEN ERADICATION BY PHAGE THERAPY IN PATIENTS WITH CHRONIC BACTERIAL PROSTATITIS

  2010cited by this paper
• Rule-based simulation of temperate bacteriophage infection: Restriction-modification as a limiter to infection in bacterial populations

  2010cited by this paper
• Head of German NICE was sacrificed to satisfy drug industry, says German health expert

  2010cited by this paper
• Bacteriophage host range and bacterial resistance.

  2010cited by this paper
• Stoking the antibiotic pipeline

  2010cited by this paper
• The changing epidemiology of resistance.

  2009cited by this paper
• Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial.

  2009cited by this paper
• Bacteriophage therapy for the treatment of infections.

  2009influential reference
• Characterization of a T7-Like Lytic Bacteriophage of Klebsiella pneumoniae B5055: A Potential Therapeutic Agent

  2009cited by this paper
• Quantitative Models of In Vitro Bacteriophage–Host Dynamics and Their Application to Phage Therapy

  2009cited by this paper
• Antibiotic-resistant bugs in the 21st century--a clinical super-challenge.

  2009cited by this paper
• Kinetics of Phage-Mediated Biocontrol of Bacteria

  2009cited by this paper
• Preventing biofilms of clinically relevant organisms using bacteriophage.

  2009influential reference
• A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses

  2009cited by this paper
• Has the era of untreatable infections arrived?

  2009influential reference
• Eradication of Enterococcus faecalis by phage therapy in chronic bacterial prostatitis — case report

  2009cited by this paper
• A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic‐resistant Pseudomonas aeruginosa; a preliminary report of efficacy

  2009cited by this paper
• Bacteriophage interactions with phagocytes and their potential significance in experimental therapy

  2009cited by this paper
• Prostatitis and male pelvic pain syndrome: diagnosis and treatment.

  2009cited by this paper
• Bacterial prostatitis.

  2008cited by this paper
• Adverse events associated with prolonged antibiotic use

  2008cited by this paper
• Bacteriophage genomics.

  2008cited by this paper
• Evaluation of Clostridium difficile-Associated Diarrhea With a Drug Formulary Change in Preferred Fluoroquinolones

  2008cited by this paper
• Chronic bacterial prostatitis (NIH type II): diagnosis, therapy and influence on the fertility status

  2008influential reference
• Identification of novel plasmid-mediated extended-spectrum beta-lactamase CTX-M-57 in Salmonella enterica serovar Typhimurium.

  2008cited by this paper
• Is phage therapy acceptable in the immunocompromised host?

  2008cited by this paper
• Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice.

  2008cited by this paper
• Bacteriophage therapy in children: facts and prospects.

  2008cited by this paper
• Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes.

  2008influential reference
• Epidemiology of prostatitis.

  2008cited by this paper
• Bacteriophage in polar inland waters

  2008cited by this paper
• Management of bacterial prostatitis: what’s new?

  2008cited by this paper
• Spectrum and antibiotic resistance of uropathogens from hospitalised patients with urinary tract infections: 1994-2005.

  2008cited by this paper
• Current treatment options in the management of chronic prostatitis

  2007influential reference
• Prior antibiotics and risk of antibiotic-resistant community-acquired urinary tract infection: a case-control study.

  2007cited by this paper
• Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome.

  2007cited by this paper
• Phage-Antibiotic Synergy (PAS): β-Lactam and Quinolone Antibiotics Stimulate Virulent Phage Growth

  2007cited by this paper
• Bacteriophages: an appraisal of their role in the treatment of bacterial infections.

  2007cited by this paper
• Dispersing biofilms with engineered enzymatic bacteriophage

  2007cited by this paper
• Biotechnological challenges of phage therapy

  2007cited by this paper
• Biofilm formation in uropathogenic Escherichia coli strains: relationship with prostatitis, urovirulence factors and antimicrobial resistance.

  2007cited by this paper
• Bacteriophages in medicine.

  2007influential reference
• Mechanisms of antimicrobial resistance in bacteria.

  2006cited by this paper
• Bacteriophage precision drug against bacterial infections

  2006cited by this paper
• Increased oxidative stress and oxidative damage associated with chronic bacterial prostatitis.

  2006cited by this paper
• Effects of bacteriophages on free radical production and phagocytic functions

  2006cited by this paper
• Preventing osteoporosis-related fractures: an overview.

  2006cited by this paper
• Phage therapy: facts and fiction.

  2006cited by this paper
• Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa.

  2006cited by this paper
• Bacteriophages and transplantation tolerance.

  2006cited by this paper
• Cure of chronic prostatitis presumably due to Enterococcus spp and gram-negative bacteria

  2006influential reference
• Augmentation of the Antimicrobial Efficacy of Antibiotics by Filamentous Phage

  2006cited by this paper
• Alpha-blockers for the treatment of prostatitis-like syndromes.

  2006cited by this paper
• Phage Therapy - Everything Old is New Again.

  2006cited by this paper
• Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremia.

  2006cited by this paper
• A diversity of bacteriophage forms and genomes can be isolated from the surface sands of the Sahara Desert

  2005cited by this paper
• alpha-Blockers for Treatment of the Prostatitis Syndromes.

  2005cited by this paper
• Antimicrobial safety: focus on fluoroquinolones.

  2005cited by this paper
• The potential role of endogenous bacteriophages in controlling invading pathogens

  2005cited by this paper
• α-Blockers for Treatment of the Prostatitis Syndromes

  2005cited by this paper
• The role of antibiotics in chronic bacterial prostatitis.

  2005cited by this paper
• Prostatitis: Epidemiology of inflammation

  2005cited by this paper
• Prevalence, diagnosis, characterization, and treatment of prostatitis, interstitial cystitis, and epididymitis in outpatient urological practice: the Canadian PIE Study.

  2005cited by this paper
• Bacteriophage P100 for control of Listeria monocytogenes in foods: genome sequence, bioinformatic analyses, oral toxicity study, and application.

  2005cited by this paper
• What's New in Prostate Cancer, Benign Prostatic Hyperplasia, and Minimally Invasive Surgery?: Highlights from the XIXth Congress of the European Association of Urology, March 23-27, 2004, Vienna, Austria.

  2005cited by this paper
• On the relevance of gram-positive bacteria in prostatitis

  2005cited by this paper
• Bacteriophage penetration in vertebrates

  2005influential reference
• Human Volunteers Receiving Escherichia coli Phage T4 Orally: a Safety Test of Phage Therapy

  2005cited by this paper
• The influence of a non-ionic surfactant on rectal absorption of virus particles

  2005cited by this paper
• Role of biofilm in catheter-associated urinary tract infection.

  2004cited by this paper
• Phage Community Dynamics in Hot Springs

  2004cited by this paper
• Antimicrobial drug discovery through bacteriophage genomics

  2004cited by this paper
• Bacteriophage Therapy in Humans

  2004cited by this paper
• [Use of therapeutic polycomponent vaccine "Immunovac VP-4" for the treatment of chronic bacterial prostatitis].

  2004cited by this paper
• The interaction of phage and biofilms.

  2004cited by this paper
• Population and evolutionary dynamics of phage therapy

  2004cited by this paper
• [Use of therapeutic polycomponent vaccine "Immunovac VP-4" for the treatment of chronic bacterial prostatitis].

  2004cited by this paper
• In Vitro and In Vivo Bacteriolytic Activities of Escherichia coli Phages: Implications for Phage Therapy

  2004cited by this paper
• Failure to eradicate Group A beta-haemolytic streptococci (GABHS) from the upper respiratory tract after antibiotic treatment.

  2004cited by this paper
• Models of phage growth and their applicability to phage therapy.

  2004cited by this paper
• α-Blockers in prostatitis

  2004cited by this paper
• Azithromycin: 4.5- or 6.0- Gram Dose in the Treatment of Patients with Chronic Prostatitis Caused by Chlamydia trachomatis - A Randomized Study

  2004cited by this paper
• Bacterial biofilm formation on urologic devices and heparin coating as preventive strategy.

  2004cited by this paper
• New dawn for phage therapy.

  2004cited by this paper
• Bacteriophage observations and evolution.

  2003influential reference
• Penetration of Antimicrobial Agents into the Prostate

  2003cited by this paper
• Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study.

  2003cited by this paper
• Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis.

  2003cited by this paper
• Epidemiology of prostatitis: new evidence for a world-wide problem

  2003cited by this paper
• Current Treatment Options

  2003cited by this paper
• The application of biofilm science to the study and control of chronic bacterial infections.

  2003cited by this paper
• Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome.

  2003cited by this paper
• A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index.

  2002cited by this paper
• PART 172—FOOD ADDITIVES PERMITTED FOR DIRECT ADDITION TO FOOD FOR HUMAN CONSUMPTION

  2002cited by this paper
• Bacteriophages: evolution of the majority.

  2002cited by this paper
• Clinical implications of antibiotic-induced endotoxin release in septic shock

  2002cited by this paper

• From Gut to Reproductive Health: Exploring Microbiome Interactions and Future Interventions

  2025cites this paper
• Male accessory gland infection (MAGI): Over-diagnosed or under treated in infertile men?

  2024cites this paper
• Phage for cancer therapy.

  2023cites this paper
• Case report: Successful treatment of recurrent E. coli infection with bacteriophage therapy for patient suffering from chronic bacterial prostatitis

  2023cites this paper
• Fluoroquinolone resistance in urinary tract infections: Epidemiology, mechanisms of action and management strategies

  2023cites this paper
• [Infections and male infertility].

  2023cites this paper
• Successful use of a phage endolysin for treatment of chronic pelvic pain syndrome/chronic bacterial prostatitis

  2023cites this paper
• Pharmacotherapeutic interventions for the treatment of bacterial prostatitis

  2022cites this paper
• Phage Revolution Against Multidrug-Resistant Clinical Pathogens in Southeast Asia

  2022cites this paper
• Successful First Use of a Phage Endolysin for Treatment of Chronic Pelvic Pain Syndrome/Chronic Bacterial Prostatitis

  2022cites this paper
• Recent advances in bacteriophage-based therapeutics: Insight into the post-antibiotic era

  2022cites this paper
• Isolation and Functional Characterization of Fusobacterium nucleatum Bacteriophage.

  2021cites this paper
• Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections

  2021cites this paper
• Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application

  2021cites this paper
• Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?

  2021cites this paper
• A Novel Phage Cocktail Therapy of the Urinary Tract Infection in a Mouse Model.

  2021cites this paper
• Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments

  2021cites this paper
• Management of Chronic Bacterial Prostatitis

  2020cites this paper
• Standardized bacteriophage purification for personalized phage therapy

  2020cites this paper
• Application of bacteriophages isolated from sewage to control urinary O157:H7 Escherichia coli and several bacterial uropathogens

  2020cites this paper
• Phage Prevalence in the Human Urinary Tract—Current Knowledge and Therapeutic Implications

  2020cites this paper
• Standardized bacteriophage purification for personalized phage therapy

  2020cites this paper
• Pharmacological Interventions for Bacterial Prostatitis

  2020cites this paper
• Implications of Bacteriophage- and Bacteriophage Component-Based Therapies for the Clinical Microbiology Laboratory

  2019cites this paper
• Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections.

  2019cites this paper
• Bacteriophages of the lower urinary tract

  2019cites this paper
• Phage therapy for severe bacterial infections: a narrative review

  2019cites this paper
• Bacterial Resistance to Phage and Its Impact on Clinical Therapy

  2019cites this paper
• Phage Pharmacokinetics: Relationship with Administration Route

  2019cites this paper
• Bacteriophages inhibit biofilms formed by multi-drug resistant bacteria isolated from septic wounds

  2019cites this paper
• Phage Therapy in Prostatitis: Recent Prospects

  2018cites this paper
• Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?

  2018cites this paper
• Bacteriophage Therapy: An Unforgetten Source of Cure

  2018cites this paper
• Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections

  2018cites this paper
• The use of bacteriophages to biocontrol oral biofilms.

  2017cites this paper
• BACTERIOPHAGE ISOLATION FROM DENTURE BIOFILM

  2017cites this paper
• Male accessory gland inflammation, infertility, and sexual dysfunctions: a practical approach to diagnosis and therapy

  2017cites this paper
• Phagothérapie : des bactériophages pour traiter les infections bactériennes

  2017cites this paper
• In Vivo Assessment of Phage and Linezolid Based Implant Coatings for Treatment of Methicillin Resistant S. aureus (MRSA) Mediated Orthopaedic Device Related Infections

  2016cites this paper
• In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice.

  2016cites this paper
• Bacteriophages as Potential Treatment for Urinary Tract Infections

  2016cites this paper
• Investigating the potentials of phage therapy in burkholderia pseudomallei infection / Ong Guang Han

  2016cites this paper
• Viruses That Can Cure, When Antibiotics Fail...

  2015cites this paper
• Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy.

  2014cites this paper
• Qu’est-ce que la phagothérapie ?

  2014cites this paper
• Bacteriophages and their enzymes in biofilm control.

  2014cites this paper
• Microbiological investigation in male infertility: a practical overview.

  2014cites this paper
• Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections

  2014cites this paper
• Phage Therapy: Eco-Physiological Pharmacology

  2014cites this paper
• Isolation and characterisation of six novel mycobacteriophages and investigation of their antimicrobial potential in milk

  2013cites this paper
• Markers of semen inflammation: supplementary semen analysis?

  2013cites this paper
• Optimizing the European Regulatory Framework for Sustainable Bacteriophage Therapy in Human Medicine

  2012cites this paper
• Synergistic Action of Gentamicin and Bacteriophage in a Continuous Culture Population of Staphylococcus aureus

  2012cites this paper
• Bacteriophages as twenty-first century antibacterial tools for food and medicine

  2011cites this paper
• La phagothérapie : passé et avenir (faits nouveaux et procédure[s] pour une réhabilitation)

  2011cites this paper
• Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens

  2011cites this paper
• Improved Adsorption of an Enterococcus faecalis Bacteriophage ΦEF24C with a Spontaneous Point Mutation

  2011cites this paper
• Phage treatment of human infections

  2011cites this paper
• Use of live phages for therapy on a background of coevolution of bacteria and phages

  2011cites this paper
• 1 TITLE : Indications and limitations of phage therapy in human medicine : Personal experience and literature review

  year unknowncites this paper